{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:10:17Z","timestamp":1764936617834},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T00:00:00Z","timestamp":1334620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11096-012-9633-3","type":"journal-article","created":{"date-parts":[[2012,4,16]],"date-time":"2012-04-16T11:34:46Z","timestamp":1334576086000},"page":"422-425","source":"Crossref","is-referenced-by-count":23,"title":["Telbivudine myopathy in a patient with chronic hepatitis B"],"prefix":"10.1007","volume":"34","author":[{"given":"Min","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Da","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haodong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,17]]},"reference":[{"issue":"2","key":"9633_CR1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97\u2013107.","journal-title":"J Viral Hepat"},{"issue":"4","key":"9633_CR2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","volume":"45","author":"JF Perz","year":"2006","unstructured":"Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529\u201338.","journal-title":"J Hepatol"},{"issue":"23","key":"9633_CR3","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2174\/092986706778521995","volume":"13","author":"G Borgia","year":"2006","unstructured":"Borgia G, Gentile I. Treating chronic hepatitis B: today and tomorrow. Curr Med Chem. 2006;13(23):2839\u201355.","journal-title":"Curr Med Chem"},{"issue":"2","key":"9633_CR4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136(2):486\u201395.","journal-title":"Gastroenterology"},{"issue":"12","key":"9633_CR5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1365-2893.2010.01412.x","volume":"18","author":"XJ Zou","year":"2011","unstructured":"Zou XJ, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J Viral Hepat. 2011;18(12):892\u20136.","journal-title":"J Viral Hepat"},{"issue":"5","key":"9633_CR6","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1590-8658(02)80136-0","volume":"34","author":"V Ojetti","year":"2002","unstructured":"Ojetti V, Gasbarrini A, Migneco A, Flore R, Santoliquido A, De Martini D, et al. Lamivudine-induced muscle mitochondrial toxicity. Dig Liver Dis. 2002;34(5):384\u20135.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"9633_CR7","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.22959","volume":"49","author":"JI Seok","year":"2009","unstructured":"Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology. 2009;49(6):2080\u20136.","journal-title":"Hepatology"},{"issue":"46","key":"9633_CR8","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.3748\/wjg.13.6150","volume":"13","author":"DN Amarapurkar","year":"2007","unstructured":"Amarapurkar DN. Telbivudine: a new treatment for chronic hepatitis B. World J Gastroenterol. 2007;13(46):6150\u20135.","journal-title":"World J Gastroenterol"},{"issue":"Suppl 1","key":"9633_CR9","first-page":"119","volume":"12","author":"DN Standring","year":"2001","unstructured":"Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother. 2001;12(Suppl 1):119\u201329.","journal-title":"Antivir Chem Chemother"},{"key":"9633_CR10","unstructured":"Weaver M, Wolf A, Persohn E, Grenet O, Pognan F. Absence of mitochondrial toxicity of telbuvidine in skeletal muscle cells, hepatocytes, and neuronal cells from rat or human. In: Abstract from the 19th Asian Pacific Association for the Study of the Liver (APASL), February 13\u201316, 2009, Hong Kong; 2009."},{"issue":"4","key":"9633_CR11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2009.04.019","volume":"51","author":"BK Kim","year":"2009","unstructured":"Kim BK, Oh J, Kwon SY, Choe WH, Ko SY, Rhee KH, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol. 2009;51(4):829\u201334.","journal-title":"J Hepatol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-012-9633-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-012-9633-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-012-9633-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T05:54:36Z","timestamp":1559368476000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-012-9633-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,17]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["9633"],"URL":"https:\/\/doi.org\/10.1007\/s11096-012-9633-3","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,17]]}}}